about
DPP-4 inhibitor plus SGLT-2 inhibitor as combination therapy for type 2 diabetes: from rationale to clinical aspects.Pharmacokinetic Characteristics and Clinical Efficacy of an SGLT2 Inhibitor Plus DPP-4 Inhibitor Combination Therapy in Type 2 Diabetes.The role of dipeptidylpeptidase-4 inhibitors in management of cardiovascular disease in diabetes; focus on linagliptin.
P2860
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Empagliflozin/Linagliptin: A Review in Type 2 Diabetes.
@en
type
label
Empagliflozin/Linagliptin: A Review in Type 2 Diabetes.
@en
prefLabel
Empagliflozin/Linagliptin: A Review in Type 2 Diabetes.
@en
P2860
P1433
P1476
Empagliflozin/Linagliptin: A Review in Type 2 Diabetes.
@en
P2093
Emma D Deeks
Esther S Kim
P2860
P2888
P304
P356
10.1007/S40265-015-0457-Z
P577
2015-09-01T00:00:00Z
P6179
1017559252